Pediatric Patients
Designed to be simple in a severe hypoglycemia rescue
Product features1:
- Dry nasal powder form of glucagon
- No inhalation required—absorbed passively in the nose
- Single, fixed, 3 mg dose
- Ready to use with no reconstitution or priming
- Does not need to be refrigerated, store at temperatures up to 86°F (30°C) in the shrink-wrapped tube provided
BAQSIMI can be used for 2 years from the date of manufacture. Instruct patients to check the expiration date on the BAQSIMI tube and carton before use.1,4
Contraindications
BAQSIMI is contraindicated in patients with pheochromocytoma because of risk of substantial increase in blood pressure , insulinoma because of risk of hypoglycemia, and known hypersensitivity to glucagon or to any of the excipients in BAQSIMI. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.
In a severe hypoglycemia emergency, BAQSIMI offers:
1. 100% of pediatric patients achieved treatment success with BAQSIMI 1,*
Treatment success† for BAQSIMI and glucagon for injection
Show Description
This bar graph shows measures of treatment success for BAQSIMI (3 milligrams) and for glucagon for injection (1 milligram) in a study of pediatric patients. One hundred percent of pediatric patients treated with BAQSIMI and 100 percent of pediatric patients treated with glucagon for injection achieved treatment success as defined in the study.
*The mean nadir blood glucose across different age cohorts was 67-73 mg/dL for BAQSIMI and 69-72 mg/dL for glucagon for injection.2
†Treatment success was defined as an increase in plasma glucose of ≥20 mg/dL from the nadir glucose concentration within 30 minutes of glucagon dosing.
Study Design
- A randomized, multicenter study that evaluated the PK/PD, safety, and efficacy of BAQSIMI compared with glucagon for injection in children and adolescents aged 4 to <17 years with type 1 diabetes (n=48) divided into 3 cohorts.2
- Young children (ages 4 to <8 years, n=18) and children (ages 8 to <12 years, n=18) were randomized 2:1 to receive either BAQSIMI 2 mg or 3 mg at visit 1 and the alternative BAQSIMI dose at visit 2, or weight-based glucagon for injection at a single study visit. Adolescents (ages 12 to <17, n=12) were randomized 1:1 to receive BAQSIMI 3 mg or glucagon for injection 1 mg with crossover to alternate glucagon at dosing visit 2. Insulin was used to reduce blood glucose levels, and glucagon was administered after glucose reached <80 mg/dL.2
SELECT IMPORTANT SAFETY INFORMATION
Warnings and Precautions
BAQSIMI is contraindicated in patients with pheochromocytoma because glucagon may stimulate release of catecholamines from the tumor. If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.
2. Portable dry nasal spray glucagon
Be prepared with BAQSIMI. The first and only dry nasal spray to treat low blood sugar emergencies
BAQSIMI offers temperature-stable portability.
Patients can carry it with them throughout the day, in hot or cold conditions, and store at up to 86°F (30°C).
BAQSIMI can be taken with you, even in freezing temperatures.
In a study, BAQSIMI was exposed to freezing temperatures as low as -4°F (-20°C) with no adverse effects to the physical, chemical, or performance characteristics of the product.
BAQSIMI can be stored for two years from date of manufacture in the shrink-wrapped tube provided, at temperatures up to 86°F (30°C). Always check the expiration date on the BAQSIMI tube and carton before use.1,4
3. Simplicity of nasal administration
Before BAQSIMI is needed:
- Read the Instructions for Use for BAQSIMI before using it.
- You should make sure you show your caregivers, family and friends where you keep BAQSIMI and explain how to use it by sharing these instructions. They need to know how to use BAQSIMI before an emergency happens.
Important information to know:
- Do not remove the Shrink Wrap or open the Tube until you are ready to use it.
- If the Tube has been opened, BAQSIMI could be exposed to moisture. This could cause BAQSIMI not to work as expected.
- BAQSIMI will work even if you have a cold or are taking cold medicine.
Preparing the dose:
Remove the Shrink Wrap by pulling on the red stripe.
Open the Lid and remove the Device from the Tube.
Caution: Do not press the Plunger until ready to give the dose.
Giving the dose
Hold Device between fingers and thumb.
Do not push Plunger yet.
Insert Tip gently in one nostril until finger(s) touch the outside of the nose.
Push Plunger firmly all the way in. Dose is complete when the Green Line disappears.
After giving BAQSIMI:
- Call for emergency medical help right away
- If the person is unconscious, turn the person on their side
- Throw away the used Device and Tube
- Encourage the person to eat as soon as possible. When they are able to safely swallow, give the person a fast-acting source of sugar, such as juice. Then encourage the person to eat a snack, such as crackers with cheese or peanut butter
- If the person does not respond after 15 minutes, another dose may be given, if available
Discover the simplicity of nasal administration with BAQSIMI
References:
- Baqsimi. Prescribing Information. Amphastar Pharmaceuticals, Inc.
- Sherr JL, Ruedy KJ, Foster NC, et al. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care. 2016;39(4):555-562.
- Pack BW, Melnick J, Breen C, Allen R. Portability of nasal glucagon for the rescue of severe hypoglycemia: stability and performance evaluation across a broad range of temperatures. Diabetes. 2021; 70(suppl 1).
- Data on File, Amphastar Pharmaceuticals, Inc.
- Baqsimi. Instructions For Use. Amphastar Pharmaceuticals, Inc.